9W3U
Structure of Csm6 from Actinomyces procaprae
Summary for 9W3U
| Entry DOI | 10.2210/pdb9w3u/pdb |
| EMDB information | 65609 |
| Descriptor | Csm6 (1 entity in total) |
| Functional Keywords | csm6, ancillary nuclease, cyclic oligoadenylate, type iii crispr, immune system |
| Biological source | Actinomyces procaprae |
| Total number of polymer chains | 4 |
| Total formula weight | 342149.56 |
| Authors | |
| Primary citation | Shi, R.,Yang, M.,Liu, Y.,Gao, H.,Lin, Z. Mechanistic basis for selective Csm6-2 activation by cyclic penta-adenylate in a type III CRISPR-Cas system. Embo J., 2026 Cited by PubMed Abstract: Type III CRISPR systems generate cyclic oligoadenylate (cOA, 3 to 6 AMPs) messengers upon detecting viral RNA, activating downstream effectors to defend against viral infection. Although cOA-activated effectors have been extensively characterized, the effectors specific to cA5-one of the most abundant cOA species produced during phage infection-have remained unexplored. Here, we report that the CRISPR ribonuclease Csm6 (Csm6-2) from Actinomyces procaprae selectively employs cA5 as its activator. Csm6-2 utilizes its HEPN domain, rather than the CARF domain, to mediate self-limiting cleavage of cOA activators. Cryo-EM structural analyses reveal that Csm6-2 functions as a homotetramer, and disruption of tetramer formation significantly reduces its ribonuclease activity. Although cA6 and cA5 bind Csm6-2 with comparable affinity, only cA5 induces CARF domain closure, stabilizes the tetramer, and remodels the active site in the HEPN domain. In contrast, the sixth AMP of cA6 imposes significant steric hindrance on CARF domain movement, preventing its closure and subsequent allosteric activation. These findings expand our understanding of the cOA signaling diversity and specific cOA recognition mechanisms in type III CRISPR immunity. PubMed: 41917262DOI: 10.1038/s44318-026-00767-3 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (2.53 Å) |
Structure validation
Download full validation report






